NCT05944978View on ClinicalTrials.gov

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Relapsed/Refractory Chronic Lymphocytic Leukemia
Interventions
DRUG

GNC-035

GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.

Trial Locations (1)

300020

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05944978 - A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies | Biotech Hunter | Biotech Hunter